En Es
Categories

Industry News

Seegene Develops World’s First Multiplex MDx Assays with AI System

By Labmedica International staff writers
09 Jan 2018

Image: Seegene has developed the world’s first molecular diagnostics assays using an artificial intelligence-based automated assay development system (Photo courtesy of Seegene).Seegene Inc. (Seoul, South Korea), a developer of multiplex PCR technologies, successfully developed molecular diagnostics (MDx) assays in just four days using an artificial intelligence- (AI) based automated assay development system. These assays are high multiplex real-time PCR reagents developed completely by AI and are meant for the simultaneous detection of eight different DNA targets for each of meningitis and sexually transmitted infections.

The Seegene Digitalized Development System (SG-DDS) automates real-time PCR assay development by utilizing big data of causative agents for diseases, Seegene's novel algorithms, and in silico oligonucleotide design with virtual experiments. This significantly reduces the time and labor required for R&D and simplifies the complicated real time PCR assay development processes, thereby allowing even non-professionals to easily develop multiplex MDx assays according to their requirement.

"The performance (sensitivity and specificity) of the assays developed by AI are equivalent to or even better than that of those manually developed," said a spokesperson from Seegene. "Only four days were sufficient by the AI system to successfully develop two 8-plex assays, while more than a year was required by a team of experienced professionals."

"We have already witnessed AI surpassing human intelligence in developing medical devices. Therefore, all molecular diagnostic assays will be developed by AI instead of professional researchers," added Dr. Jong-Yoon Chun, CEO and Founder of Seegene. "SG-DDS is now the most economical solution to MDx assay development as it saves time and labor, and will ultimately drive down the cost of molecular diagnostic tests, one of the biggest obstacles in MDx market. SG-DDS will lead to standardization of MDx system and promote tailor-made medical treatment."



E-mail Print
FaceBook Twitter Google+ Linked in

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology. The company’s products detect multi-pathogens with high sensitivity, specificity and reproducibility, resulting in saving of time, labor and cost.
More info

More articles about Seegene

19 Apr 2018
Seegene Unveils Combination Test at ECCMID 2018
Seegene Inc., a developer of multiplex PCR technologies, introduced a combination test at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) held in Madrid, Spain, from April 21 to 24, 2018. The combination test is a high-efficiency solution that diagnoses various causes of diseases with multiplex molecular diagnosis assays. Seegene also showcased its molecular diagnostic system SGSTAR (Seegene Sameday Test and Report), which allows order-to-report on the same day and enables the running of the combination test.
Read More
28 Sep 2017
Seegene Partners with Hamilton to Develop Random Access System
Seegene, a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx), has signed a Memorandum of Understanding (MoU) with Hamilton Company, which designs and manufactures precision measurement devices, automated liquid handling workstations, and sample management systems, to develop the Seegene Random Access System.
Read More
29 May 2017
Seegene Collaborates with Thermo to Enter US Market
Seegene Inc., a developer of multiplex molecular diagnostics technologies and assays, has entered into a collaboration with Thermo Fisher Scientific, in which Seegene will file for U.S. Food and Drug Administration (FDA) clearance of its Allplex diagnostic assay portfolio at the same time that Thermo Fisher files for FDA clearance to run Seegene's assays on Thermo Fisher's QuantStudio 5 Real-Time PCR System (PCR System).
Read More

Additional news

24 Apr 2018
Fujifilm Showcases Extended Product Line at ECR 2018
Fujifilm Medical Systems Europe, a provider of diagnostic imaging products and medical informatics solutions, showcased its broad, enhanced line up of products and solutions at the European Congress of Radiology (ECR) 2018. The products and solutions showcased by Fujifilm at ECR 2018 focused on women’s health, healthcare IT, artificial intelligence (AI), digital radiography (DR), computed tomography (CT), computed radiography and ultrasound.
Read More
24 Apr 2018
AI Device for Diabetic Retinopathy Receives FDA Approval
The first-ever medical device to use artificial intelligence (AI) for detecting diabetic retinopathy has received marketing approval from the US Food and Drug Administration (FDA). The AI-based diagnostic system named IDx-DR, which has been developed by privately-held AI diagnostics company IDx, is the first device to be authorized for marketing that provides a screening decision without the need for a clinician to also interpret the image or results. This means that the device can also be used by health care providers who may not normally be involved in eye care.
Read More
24 Apr 2018
AI-Based Platform Designed to Classify Strokes Quickly
An artificial intelligence (AI)-based stroke diagnosis platform designed to assist doctors in quickly classifying the cause of a stroke has completed clinical trials and is expected to provide key information to determine treatment for stroke, leading to faster and more-precise decision-making for patients.
Read More
24 Apr 2018
Breast Density Assessment Software Receives FDA Clearance
The US Food and Drug Administration (FDA) has given 510(k) clearance to a machine learning breast density assessment software that empowers radiologists with standardized, personalized and automated density reports to optimize women’s breast health and follow-up care decisions. The software is now cleared for clinical use in the US, Europe, Canada and Australia, and is the first of several follow-on products to be launched by Densitas Inc., a developer of breast imaging analytics.
Read More
18 Apr 2018
Breast Imaging Market Worth USD 7 Billion by 2024
The global breast imaging market size was estimated at USD 2.9 billion in 2016 and is expected to reach USD 7.3 billion by 2024, driven by the increasing prevalence of breast cancer and other breast-related diseases such as infections, lesions and fibrocysts, as well as supportive government initiatives to increase awareness.
Read More
17 Apr 2018
Veritas Capital Acquires IT Unit of GE Healthcare
Veritas Capital, a private equity investment firm, has entered into a definitive agreement with General Electric, to acquire the Enterprise Financial Management (Revenue-Cycle, Centricity Business), Ambulatory Care Management (Centricity Practice Solution) and Workforce Management (formerly API Healthcare) assets comprising GE Healthcare’s Value-Based Care Division for USD 1.05 billion in cash.
Read More
16 Apr 2018
Interactive VR Assists in Treatment Planning
Interactive virtual reality (VR) shows a patient's unique internal anatomy to interventional radiologists in order to help physicians effectively prepare and tailor their approach to complex treatments, such as splenic artery aneurysm repair. In a new study, researchers compared the VR technology to the use of images from a commonly used visualization software system that displays images on a standard two-dimensional platform and found the accuracy to be similar with both methods, though confidence improved substantially with VR.
Read More
05 Apr 2018
New AI Technique Dramatically Improves Quality of Medical Imaging
Researchers have developed a new technique based on artificial intelligence (AI) and machine learning that enables radiologists to acquire higher quality images without having to collect additional data at the cost of increased radiation dose for computed tomography (CT) and positron emission tomography (PET) or uncomfortably long scan times for magnetic resonance imaging (MRI).
Read More
05 Apr 2018
Canon Medical Systems Initiates Collaborative Research On AI in MR Imaging
Canon Medical Systems Corporation, along with Kumamoto University and the University of Bordeaux, has initiated collaborative research on the application of Deep Learning Reconstruction (DLR), an Artificial Intelligence (AI)-based technology in magnetic resonance (MR) imaging.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions